Research Analyst Related Topics 
The Pharma Data
AUGUST 20, 2020
The latest results underscore that large pharma companies are making a “strategic retreat from some of their older drugs,” in China, ICBC International Research analyst Zhang Jialin said, as quoted by Bloomberg; instead, they’re focusing on growing market share for newer medicines. It’s not a completely unforeseen shift, though.
ACRP blog
NOVEMBER 8, 2023
“With retail pharmacies entering the clinical trial space, investigative sites are left with little information around how this move will affect them or their patients,” says Emily Botto, Senior Research Analyst at the Tufts Center for the Study of Drug Development (CSDD) and a scheduled presenter at the ACRP 2024 conference in Anaheim, Calif.
This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Pharmaceutical Technology
MARCH 17, 2023
Over the last twenty years, there has been a major rise in risk sharing agreements in the pharmaceutical space, said Alex Watt, GlobalData’s principal research analyst, at a recent webinar on the same topic.
Pharmaceutical Technology
JANUARY 27, 2023
Designing risk sharing agreements Overall however, this warranty program is similar to previous performance-based risk sharing agreements, says Alex Watt, principal research analyst on GlobalData’s Price Intelligence team. GlobalData is the parent company of Pharmaceutical Technology.
XTalks
APRIL 13, 2021
Kyle Gaan, a research analyst at GFI said in the same press release, “2020 was a breakout year for plant-based foods across the store. The growth can also be attributed to the placement of plant-based meat in the meat section, with refrigerated plant-based meat sales growing twice as fast as their frozen counterparts.
XTalks
JUNE 9, 2022
Tirzepatide’s continuing stellar trial results as a weight loss injection have industry analysts putting up big predictions for the drug, particularly as a rival to Novo’s obesity drug Wegovy (tirzepatide is currently only approved for the treatment of type 2 diabetes under the trade name Mounjaro). billion in sales by 2026.
Roots Analysis
OCTOBER 12, 2023
For detailed insights about this domain, check out our report on Digital Twin Market Author’s Bio Gaurav Raj Bangarh is a business research analyst and competitive intelligence professional. As a senior analyst at Roots Analysis, Gaurav has assisted several clients across multiple industry verticals within the healthcare domain.
Expert insights. Personalized for you.
52 
Let's personalize your content